Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV116 vs Paxlovid for SARS-CoV-2 rebound in mild-to-moderate COVID-19
ChiCTR2200066811Phase 3Completed
- Sponsor
- Ruijin Hospital
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing VV116 arm with Paxlovid arm (2 arms). Primary endpoint: SARS-CoV-2 rebound rate by quantitative RT-PCR within 60 days. Started Dec 2022; status: completed.
02
Drugs
deuremidevirNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200066811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066811.